Notifiable diagnoses

Notifiable diagnoses according to ICD10

All C-diagnoses must be reported, with the exception of C44 Basal cell carcinoma and Squamous cell carcinoma.

In addition, these diagnoses must be reported:

D051    Intraductal carcinoma in situ

D06      Carcinoma in situ of cervix (to be reported on CIN form if
            colposcopy or conisation has been performed)   

D090    Carcinoma in situ in bladder

D091    Carcinoma in situ of second and unspecified urinary tract organs

D30      Benign neoplasm of urinary tract organs (excl. D300)
            The obligation to notify only applies to a morphological diagnosis:                Papillary urothelial neoplasm with low malignancy potential

D32      Benign neoplasm in the membranes of the central nervous system

D33      Benign tumor of brain and other parts of the CNS

D352    Benign tumor of pituitary gland

D353    Benign neoplasm of the ductus craniopharyngealis

D354    Benign neoplasm of the corpus pineale

D3910  Tumour with pathological anatomical evidence uncertain
            malignancy potential in ovary

D3911  Ovarian tumour with clinically uncertain malignancy potential

D3920  Tumour with pathological anatomical evidence uncertain
            malignant potential in placenta - applies to invasive molar                            pregnancy

D3921  Tumour with clinically uncertain placental malignancy potential -                    applies to invasive molar pregnancy

D41      Tumour with uncertain or unknown malignancy potential in
            urinary organs (excl. D410)
            The obligation to notify only applies to a morphological diagnosis:                Papillary urothelial neoplasm with low malignancy potential

D42      Tumor with uncertain or unknown target pot. in CNS membranes
            All codes within D42 are subject to notification

D43      Tumor with uncertain/unknown target pot. of the brain and CNS
            All codes within D43 are subject to notification

D4430  Tumour with pathological anatomical evidence uncertain
            malignancy potential in pituitary gland

D4431  Tumour with clinically uncertain pituitary malignancy potential

D4440  Tumour with pathological anatomical evidence uncertain
            malignancy potential in the craniopharyngeal duct

D4441  Tumour with clinically uncertain malignancy potential in
            Ductus craniopharyngealis

D4450  Tumour with pathological anatomical evidence uncertain
            malignancy potential in the corpus pineale

D4451  Tumour with clinically uncertain malignancy potential in the corpus                pineale

D45      Polycythemia vera

D46      Myelodysplastic syndromes

D471    Chronic myeloproliferative disease

D473    Hemorrhagic essential thrombocythaemia

D474    Myelofibrosis

C44 Basal cell carcinoma and squamous cell carcinoma

C44 is the ICD10 code for both basal cell carcinomas and other skin cancers (with the exception of malignant melanoma, which has ICD10 code C43).

Basal cell carcinomas and squamous cell carcinomas should not be reported in the clinical notification to the Cancer Registry. Other cancer diagnoses within C44 must be reported on the form for solid tumours. 

D39.2 Trophoblastic disease

D39.2 is trophoblastic disease, or disease of the placenta.

The benign trophoblastic tumors complete mola and partial mola should not be reported. All malignant cases should be reported. This includes cases of different levels of malignancy such as persistent trophoblastic disease, plancenta-sit-trophoblastic tumour, invasive mola, choriocarcinoma and epithelioid trophoblastic tumour.

Reporting of progression/relapse/metastases

We are often asked whether progression/relapse/metastases should be reported to the Cancer Registry of Norway via clinical notification. The main rules are as follows:

• All metastases occurring before completion of primary treatment should be reported. This applies to all cancers. As a rule, this is taken care of by the reporting that is done in connection with primary assessment, primary treatment and/or control.
• For cancers that are not included in quality registries, it is not necessary to report via clinical notification progression/relapse/metastases that occur after primary treatment has ended.
• For cancers included in quality registries, progression/relapse/metastases must be reported if there are reports covering this. It can either be separate reports of relapse or choices in specific forms (in assessment, in surgery) that concern metastases or local relapse.